Harpoon

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN

Retrieved on: 
Saturday, February 10, 2024
Renesas Electronics, Hewlett-Packard, Johnson & Johnson, Fraud, Sale, Advertising, Therapy, Transphorm, Harpoon, Electronics, Security (finance)

If you are an Ambrx shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNW

Retrieved on: 
Wednesday, February 7, 2024
Harpoon, Advertising, Fraud, First, Therapy, Sale, Security (finance)

If you are a Harpoon shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO)’s sale to Sun Pharmaceutical Industries Limited for $43.00 per share in cash.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TARO

Retrieved on: 
Thursday, January 25, 2024
Therapy, Hewlett-Packard, Harpoon, Fraud, Sale, Advertising, Johnson & Johnson, Security (finance)

If you are an Ambrx shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • If you are a Taro shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm

Retrieved on: 
Friday, January 19, 2024
Harpoon, PLLC, Human, Hawaiian Airlines, Pioneer Natural Resources, Alaska Air Group, ExxonMobil, Merck, AstraZeneca, Therapy, Security (finance)

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Under the agreement, shareholders of Hawaiian Airlines are set to receive $18.00 per share in cash.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, AMAM, HARP

Retrieved on: 
Wednesday, January 17, 2024
Therapy, FG, Harpoon, Fraud, Sale, Advertising, Johnson & Johnson, Boston Scientific, Security (finance)

If you are an FG Group shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an FG Group shareholder, click here to learn more about your rights and options .
  • If you are an Axonics shareholder, click here to learn more about your rights and options .
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on: 
Tuesday, January 16, 2024
Brodsky, Harpoon, ADS, Johnson & Johnson, AstraZeneca, BSX, JNJ, J&J, Boston Scientific, AZN, MRK, Security (finance)

BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, HARP, AMAM

Retrieved on: 
Saturday, January 13, 2024
Therapy, FG, Harpoon, Fraud, Sale, Advertising, Johnson & Johnson, Boston Scientific, Security (finance)

If you are an FG Group shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an FG Group shareholder, click here to learn more about your rights and options .
  • If you are an Axonics shareholder, click here to learn more about your rights and options .
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR

Retrieved on: 
Tuesday, January 9, 2024
Advertising, Harpoon, Eargo, Fraud, Boston Scientific, Johnson & Johnson, Sale, Therapy, Security (finance)

If you are a Harpoon shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • If you are an Axonics shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on: 
Monday, January 8, 2024
ADS, Harpoon, Johnson & Johnson, Brodsky, AstraZeneca, J&J, Boston Scientific, JNJ, AZN, MRK, BSX, Security (finance)

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)

Retrieved on: 
Monday, January 8, 2024
MSD, Harpoon, MRK, Biotechnology, Security (finance)

LONDON, 8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK).

Key Points: 
  • LONDON, 8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK).
  • The two companies have entered into a definitive agreement under which Merck (known as MSD outside the United States and Canada), through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
  • Arix will provide a full financial update for its shareholders in due course.
  • The announcement can be accessed on Harpoon Therapeutics’ website at: www.harpoontx.com and the full text of the announcement from the company is contained below.